Figure 1.




Figure 2.




Figure 3. Neutralization titers induced in sera of vaccinated mice (against hMPV A1 subgroup)

A. EXP 4719 (vaccine comprising 0.6 µg per F antigen, and 30 µg M protein)




Figure 3. Neutralization titers induced in sera of vaccinated mice (against hMPV A1 subgroup)

B. EXP 4712 (vaccine comprising 0.2 µg per F antigen)




Figure 3. Neutralization titers induced in sera of vaccinated mice (against hMPV A1 subgroup)

C. EXP 4730 (vaccine comprising 0.02 µg per F antigen)




Figure 4. Neutralization titers induced against F protein candidates derived from A1 or B1 subgroups, or combinations thereof (against hMPV A1 subgroup)

EXP 4736 (vaccine comprising 0.02 µg per F antigen)




Figure 5. Protection of mice upon challenge with the hMPV A2a subgroup: A – FFA; B - RqPCR.

EXP 4736 (vaccine comprising 0.02 µg per antigen)

A




Figure 5. Protection of mice upon challenge with the hMPV A2a subgroup: A – FFA; B - RqPCR.

B




Figure 6: Neutralization and cross-neutralization by MNA

A




Figure 6.

B



Exp4763 Neutralizing titers
(CAN97-89 #32, subgroup B1)
MNA titer
10000
1000
100
LOD
0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 µg
pre-Fusion candidate L7 (A1)
post-Fusion benchmark (A1)
pre-Fusion candidate L7 (B1)
post-Fusion benchmark (B1)

Figure 7

A



Exp4775 Neutralizing titers
(NL/1/00-101P #15 - subgroup A1)
10000
1000
100
MNA titer
LOD
0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 µg
pre-Fusion candidate 23 (A1) post-Fusion benchmark (A1)
pre-Fusion candidate 23 (A1) post-Fusion benchmark (B1)
pre-Fusion candidate 23 (B1) post-Fusion benchmark (A1)
pre-Fusion candidate 23 (B1) post-Fusion benchmark (B1)

Figure 7.

B



Exp4775 Neutralizing titers
(CAN97-82 #32, subgroup B1)
10000
1000
100
MNA titer
LOD
0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 0.04 0.12 0.40 µg
pre-Fusion candidate 23 (A1) post-Fusion benchmark (A1)
pre-Fusion candidate 23 (A1) post-Fusion benchmark (B1)
pre-Fusion candidate 23 (B1) post-Fusion benchmark (A1)
pre-Fusion candidate 23 (B1) post-Fusion benchmark (B1)

Figure 8: Adjuvant effect on induction of the hMPV neutralizing antibodies

